NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

All NICE products on transient loss of consciousness. Includes any guidance and quality standards.

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

In this blog, I’ll discuss how a new UK-wide cross-government working group, including industry trade bodies has been set up to improve patient access to innovative health technologies. The group will ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.